慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗期间的动脉闭塞事件
综述探讨酪氨酸激酶抑制剂(TKI)治疗慢性髓性白血病时动脉闭塞事件这一类效应的识别延迟原因,指出各主要临床试验不良事件报告标准不一致、按频率阈值报告、随访不足、归因尝试及以分子学反应为主要关注点等因素可能均有作用,并建议未来试验采用统一综合的不良事件报告方法。
要点
- TKI为慢性髓性白血病标准治疗,各药抑制的酪氨酸激酶谱不同,毒性谱各异。
- 动脉闭塞事件在ponatinib引入后首次被注意,后发现所有TKI均有不同程度发生。
- 各主要TKI临床试验不良事件报告标准不一致,可能导致动脉闭塞事件报告混杂。
核心结论
- 动脉闭塞事件作为TKI类效应识别延迟的原因可能多方面,包括各试验不良事件报告标准不一致、按频率阈值报告、随访不足、归因尝试及以分子学反应为主要关注点等。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- ponatinib引入后动脉闭塞事件首次被注意,后发现在所有TKI中均有不同程度发生。
- ponatinib在imatinib引入10年后才上市,类效应的识别因此延迟。
- 各主要TKI临床试验的不良事件报告标准不一致,可能导致动脉闭塞事件报告混杂。
- 按频率阈值报告事件、缺乏足够随访、尝试归因及以分子学反应为主要关注点可能均有额外作用。
- 动脉闭塞事件发生率随时间增加,许多试验仅5年后终止,妨碍全面评估这些事件的影响。
临床怎么用
- 作者认为,使用统一的《监管活动医学词典》(MedDRA)术语并对这些事件进行全面裁定,可能有助于更好地评估每种TKI对患者的真实风险。
- 作者建议,未来临床试验应采用统一综合的方法报告不良事件,而不尝试将因果归因于研究药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tyrosine kinase inhibitors (TKIs) are standard therapy for patients with chronic myeloid leukemia. Each of these drugs has a specific profile of tyrosine kinases that they inhibit and, although all are clinically effective, they each have unique toxicity profiles. With the introduction of ponatinib, arterio-occlusive events were first noted and later found to occur with all TKIs to various extents. The recognition of this "class effect" was delayed considering ponatinib was introduced 10 years after the introduction of imatinib. The reasons for the delay in identification of this class effect are likely multifaceted. Importantly, there is an inconsistency in adverse event reporting criteria among the major clinical trials of the various TKIs, likely resulting in mixed reporting of arterio-occlusive events. Reporting events based on a frequency threshold, lack of sufficient follow-up, attempts at causality attribution, and the primary focus on molecular response may all have played an additional role. Considering the increasing rate of arterio-occlusive events over time, the termination of many trials after only 5 years prevents full assessment of the impact of these events. A comprehensive evaluation of TKI adverse effects using uniform Medical Dictionary for Regulatory Activities terms and comprehensive adjudication of these events may be helpful in better assessing the real risk for patients with each TKI. Future clinical trials should use a uniform and comprehensive approach to reporting adverse events without attempting to assign causality to the study drug.
引用
- Veltmaat L, Cortes J. Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Blood. 2024. PMID: 38194683. doi:10.1182/blood.2023022403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。